<헌트 - FcRn과 이뮤노반트> - 김성민 (지은이)
바이오스펙테이터 | 2026-09-30 출간 | 18000원
알라딘 구매 링크
신약개발은 왜 성공을 예측하기 어려운가? 오랫동안 답을 찾지 못했다면 질문이 잘못되었는지도 모른다. 신약개발은 샅샅이 살피되 길목에 집중하고, 성공을 끈질기게 기다리지만 실패하면 빠르게 그리고 미련 없이 떠나서 다른 목표를 타깃해야 한다. 신약개발이 지닌 사냥의 속성을 정확하게 이해하고 실천하는, 기다리며 예측하기보다 한발 앞서 행동하는 사냥꾼들의 이야기.
바이오스펙테이터 | 2026-09-30 출간 | 18000원
알라딘 구매 링크
신약개발은 왜 성공을 예측하기 어려운가? 오랫동안 답을 찾지 못했다면 질문이 잘못되었는지도 모른다. 신약개발은 샅샅이 살피되 길목에 집중하고, 성공을 끈질기게 기다리지만 실패하면 빠르게 그리고 미련 없이 떠나서 다른 목표를 타깃해야 한다. 신약개발이 지닌 사냥의 속성을 정확하게 이해하고 실천하는, 기다리며 예측하기보다 한발 앞서 행동하는 사냥꾼들의 이야기.
October 1, 2026 at 7:35 AM
<헌트 - FcRn과 이뮤노반트> - 김성민 (지은이)
바이오스펙테이터 | 2026-09-30 출간 | 18000원
알라딘 구매 링크
신약개발은 왜 성공을 예측하기 어려운가? 오랫동안 답을 찾지 못했다면 질문이 잘못되었는지도 모른다. 신약개발은 샅샅이 살피되 길목에 집중하고, 성공을 끈질기게 기다리지만 실패하면 빠르게 그리고 미련 없이 떠나서 다른 목표를 타깃해야 한다. 신약개발이 지닌 사냥의 속성을 정확하게 이해하고 실천하는, 기다리며 예측하기보다 한발 앞서 행동하는 사냥꾼들의 이야기.
바이오스펙테이터 | 2026-09-30 출간 | 18000원
알라딘 구매 링크
신약개발은 왜 성공을 예측하기 어려운가? 오랫동안 답을 찾지 못했다면 질문이 잘못되었는지도 모른다. 신약개발은 샅샅이 살피되 길목에 집중하고, 성공을 끈질기게 기다리지만 실패하면 빠르게 그리고 미련 없이 떠나서 다른 목표를 타깃해야 한다. 신약개발이 지닌 사냥의 속성을 정확하게 이해하고 실천하는, 기다리며 예측하기보다 한발 앞서 행동하는 사냥꾼들의 이야기.
GPCR antagonism via rewiring of receptor trafficking and degradation
->Nature | More on "GPCR antagonism and receptor trafficking" at BigEarthData.ai | #trafficking
->Nature | More on "GPCR antagonism and receptor trafficking" at BigEarthData.ai | #trafficking
GPCR antagonism via rewiring of receptor trafficking and degradation
Plasmids were constructed using standard Gibson cloning methods. DNA fragments of APJ, BILF1, TfR1 scFv H7 (ref. 29), TfR1 VHH-A (ref. 30), APJ VHH JN241 (ref. 32), A2AR VH/VL domains Hu3F6 H5-L5 (ref. 33), CCR6 VH/VL domains from 4H11 (ref. 44) and Fc variants (knobs-into-holes Fc for heterobispecific constructs28, G236R/L328R/D356E/L358M and H435A variants to abolish FcγR and FcRn interactions61,62,63 and N297G variant for increased stability and developability64) were synthesized by Integrated DNA Technologies or Twist Bioscience. Binder sequences and/or Fc variants were subcloned into a pFuse-hIgG1 vector (InvivoGen) for mammalian expression. The pcDNA-FLAG–AT1R and pCDNA-FLAG–RXFP1 plasmids were obtained as previously described31,65. AT1R VHH and RXFP1 VHH were developed as previously described31,66. ADORA2A-DuET was a gift from Thomas Sakmar (Addgene plasmid 213174; http://n2t.net/addgene:213174; RRID:Addgene_213174). The pCDH-TfR-mApple lentiviral vector was a gift from Angus Johnston (Addgene plasmid 179384; http://n2t.net/addgene:179384; RRID:Addgene_179384). GPCR sequences were fused with FLAG tag, HA tag and/or GFP and subcloned into pCDH or Tet-On lentiviral vectors for stable dox-inducible expression (Supplementary Fig. 8). The TfR1 sequence was fused with a v5 tag and/or BFP and subcloned into pCDH lentiviral vector for stable overexpression. NFAT-luciferase reporter was a gift from Toren Finkel (Addgene plasmid 10959; http://n2t.net/addgene:10959; RRID:Addgene_10959). The pGloSensor cAMP...
www.nature.com
September 30, 2026 at 9:39 PM
Rozanolixizumab now sits beside efgartigimod and immunoglobulin in myasthenia gravis, but anchored and unanchored adjustments differ in weight. https://www.mattheneus.com/editorial/pubmed-rozanolixizumab-fcrn-anchored-unanchored-population-adjustment-evidence-2026-09-29 #HTA #MAIC #EvidenceSynthesis
September 29, 2026 at 12:02 PM
Rozanolixizumab now sits beside efgartigimod and immunoglobulin in myasthenia gravis, but anchored and unanchored adjustments differ in weight. https://www.mattheneus.com/editorial/pubmed-rozanolixizumab-fcrn-anchored-unanchored-population-adjustment-evidence-2026-09-29 #HTA #MAIC #EvidenceSynthesis
US20260274961A1 discloses dual-variable-domain IgGs targeting FcRn and activating FcγR to redirect immune-complex handling. FcRn/FCGR2A knockout and transgenic models, including K/B×N arthritis, test receptor dependence. Key risk: immune-complex clearance may amplify myeloid inflammation.
September 27, 2026 at 1:02 PM
US20260274961A1 discloses dual-variable-domain IgGs targeting FcRn and activating FcγR to redirect immune-complex handling. FcRn/FCGR2A knockout and transgenic models, including K/B×N arthritis, test receptor dependence. Key risk: immune-complex clearance may amplify myeloid inflammation.
Wednesday's harvest: Immunovant's IMVT-1402 missed a phase 2b cutaneous lupus trial, Roche's phase 3 kidney win opened an accelerated-approval path, and AI-driven discovery pulled ~$450M for Enveda and Basecamp Research.
https://openbionews.com/analysis/daily-bio-news-summary-2026-09-23/
https://openbionews.com/analysis/daily-bio-news-summary-2026-09-23/
Daily Bio News Summary — 2026-09-23: An FcRn reality check, Roche
Wednesday
openbionews.com
September 24, 2026 at 2:00 AM
Wednesday's harvest: Immunovant's IMVT-1402 missed a phase 2b cutaneous lupus trial, Roche's phase 3 kidney win opened an accelerated-approval path, and AI-driven discovery pulled ~$450M for Enveda and Basecamp Research.
https://openbionews.com/analysis/daily-bio-news-summary-2026-09-23/
https://openbionews.com/analysis/daily-bio-news-summary-2026-09-23/
Online now: FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology
FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology
(Cell Metabolism 37, 656–672.e1–e7; March 4, 2025)
dlvr.it
September 22, 2026 at 3:42 PM
Online now: FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
The drug is already approved as a treatment for myasthenia gravis.
September 20, 2026 at 7:28 AM
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
The drug is already approved as a treatment for myasthenia gravis.
A paper using RRID:AB_2574530 from @thermofishersci.bsky.social was just published in Cell Reports. We value the author's support of reproducibility. #reproducibility #methodsmatter #OpenResearch
Albumin uptake through FcRn promotes tumor-associated macrophage maturation and albumin-bound immunotherapy response
Read the full paper: Albumin uptake through FcRn promotes tumor-associated macrophage maturation and albumin-bound immunotherapy response
doi.org
September 20, 2026 at 7:00 AM
A paper using RRID:AB_2574530 from @thermofishersci.bsky.social was just published in Cell Reports. We value the author's support of reproducibility. #reproducibility #methodsmatter #OpenResearch
WO2026180989A1 combines CH3 P374/CH1 P151 and heterodimerisation mutations with BiP-mediated ER retention and IRE1/RIDD control to reduce mispaired chains and half-antibodies, with stability, FcRn and mouse-PK validation.
September 12, 2026 at 10:35 AM
WO2026180989A1 combines CH3 P374/CH1 P151 and heterodimerisation mutations with BiP-mediated ER retention and IRE1/RIDD control to reduce mispaired chains and half-antibodies, with stability, FcRn and mouse-PK validation.
Vědci z C E I T E C Masarykovy univerzity poprvé zachytili tento proces přímo v infikovaných buňkách.
🦠 Jak enterovirus spouští infekci buňky?
> Pomocí kryoelektronové mikroskopie zjistili, že echovirus 18 neuvolňuje svou RNA malým otvorem v kapsidě, jak se dlouho předpokládalo. Jeho proteinový obal se částečně rozpadne a vytvoří velký otvor, kterým virová genetická informace uniká do buňky.
Studie tak přináší nový pohled na jednu z nejranějších fází virové infekce.
🔬 Jakou roli v procesu hraje buněčný receptor FcRn a co dalšího vědci odhalili?
👉 Více se dozvíte v článku: nivb.cz/2026/08/11/vedci-z-cei…
social.netdynamics.eu
September 1, 2026 at 7:31 PM
Vědci z C E I T E C Masarykovy univerzity poprvé zachytili tento proces přímo v infikovaných buňkách.
yes! I actually worked on the first FcRn inhibitor for MG, and I remember telling the development team that we should study it in wAIHA, and while that team didn’t end up doing it, I’m really glad that J&J did!
August 28, 2026 at 1:37 PM
yes! I actually worked on the first FcRn inhibitor for MG, and I remember telling the development team that we should study it in wAIHA, and while that team didn’t end up doing it, I’m really glad that J&J did!
Danaher and $DHR are diagnostics I watch - qPCR/ddPCR, scRNA, MS platforms cut pre-analytical noise, lifting SNR. focus FcRn/PK raises antibody CDx value. Mispriced - 2x/12m. I use @bluestocks.app. analytcal #finsky
August 26, 2026 at 4:08 PM
Danaher and $DHR are diagnostics I watch - qPCR/ddPCR, scRNA, MS platforms cut pre-analytical noise, lifting SNR. focus FcRn/PK raises antibody CDx value. Mispriced - 2x/12m. I use @bluestocks.app. analytcal #finsky
Regeneron and $REGN: garetosmab activin A blockade proves mechanism; FcRn PK and mAb kinetics foucus/exposure argue 2x rerate. quantatative. https://www.pharmexec.com/view/fda-approves-pasatru-adults-fibrodysplasia-ossificans-progressiva
August 26, 2026 at 3:03 PM
Regeneron and $REGN: garetosmab activin A blockade proves mechanism; FcRn PK and mAb kinetics foucus/exposure argue 2x rerate. quantatative. https://www.pharmexec.com/view/fda-approves-pasatru-adults-fibrodysplasia-ossificans-progressiva
Regeneron $REGN: garetosmab activin A blockade, focus FcRn kinetcs, quantatative. https://www.pharmexec.com/view/fda-approves-pasatru-adults-fibrodysplasia-ossificans-progressiva
August 25, 2026 at 12:08 PM
Regeneron $REGN: garetosmab activin A blockade, focus FcRn kinetcs, quantatative. https://www.pharmexec.com/view/fda-approves-pasatru-adults-fibrodysplasia-ossificans-progressiva
THE FIRST FDA-APPROVED TREATMENT FOR MY RARE DISEASE IS HERE 😭😭😭 BRO I CANNOT BELIEVE THIS DAY IS HERE 😭😭😭
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
· IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function · Warm autoimmune hemolytic anemia is a...
www.jnj.com
August 24, 2026 at 11:46 PM
THE FIRST FDA-APPROVED TREATMENT FOR MY RARE DISEASE IS HERE 😭😭😭 BRO I CANNOT BELIEVE THIS DAY IS HERE 😭😭😭
As an ex-researcher I watch Regeneron $REGN: activin A mAb garetosmab validates platform; FcRn salvage + IL-4/13 kinetcs focus exposure, analysi. https://www.pharmexec.com/view/fda-approves-pasatru-adults-fibrodysplasia-ossificans-progressiva
August 23, 2026 at 3:05 PM
As an ex-researcher I watch Regeneron $REGN: activin A mAb garetosmab validates platform; FcRn salvage + IL-4/13 kinetcs focus exposure, analysi. https://www.pharmexec.com/view/fda-approves-pasatru-adults-fibrodysplasia-ossificans-progressiva
Ex-PI: Regeneron $REGN - Dupix IL4/13+FcRn salvgae=lens on kinetcs; cheap. https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-inc-regn-q2-210444875.html
August 21, 2026 at 8:05 PM
Ex-PI: Regeneron $REGN - Dupix IL4/13+FcRn salvgae=lens on kinetcs; cheap. https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-inc-regn-q2-210444875.html
#ImmunologyNews The study found that the placenta can distinguish between IgG antibodies and albumin, despite both proteins being recognised by the neonatal Fc receptor (FcRn)...#pregnancy #immunology
Read more here: https://ow.ly/Bmcc50ZBolr
Read more here: https://ow.ly/Bmcc50ZBolr
August 19, 2026 at 10:33 AM
#ImmunologyNews The study found that the placenta can distinguish between IgG antibodies and albumin, despite both proteins being recognised by the neonatal Fc receptor (FcRn)...#pregnancy #immunology
Read more here: https://ow.ly/Bmcc50ZBolr
Read more here: https://ow.ly/Bmcc50ZBolr
#ImmunologyNews The study found that the placenta can distinguish between IgG antibodies and albumin, despite both proteins being recognised by the neonatal Fc receptor (FcRn)...#pregnancy #immunology
Read more here: https://ow.ly/u5zv50ZBoir
Read more here: https://ow.ly/u5zv50ZBoir
August 19, 2026 at 10:31 AM
#ImmunologyNews The study found that the placenta can distinguish between IgG antibodies and albumin, despite both proteins being recognised by the neonatal Fc receptor (FcRn)...#pregnancy #immunology
Read more here: https://ow.ly/u5zv50ZBoir
Read more here: https://ow.ly/u5zv50ZBoir
Ex-PI: Regeneron melds IL-4/13 Dupixent, FcRn salvage and antibody kinetcs into sharp focus; $REGN mispriced-2x re-rate predicted. https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-inc-regn-q2-210444875.html
August 15, 2026 at 3:05 PM
Ex-PI: Regeneron melds IL-4/13 Dupixent, FcRn salvage and antibody kinetcs into sharp focus; $REGN mispriced-2x re-rate predicted. https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-inc-regn-q2-210444875.html
Buy $REGN. Regeneron masters antibody kinetcs, FcRN salvage; bispecific focus. https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-inc-regn-q2-210444875.html
August 15, 2026 at 12:03 PM
Buy $REGN. Regeneron masters antibody kinetcs, FcRN salvage; bispecific focus. https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-inc-regn-q2-210444875.html
Floss-Mediated Gingival Mucosal Immunization with HBc-E18-3 VLPs Induces Long-Lasting Intestinal IgG and Provides a Candidate Strategy for Intervention of FcRn-Related Autoimmune Injury https://www.biorxiv.org/content/10.64898/2026.08.10.743934v1
August 15, 2026 at 4:15 AM
Floss-Mediated Gingival Mucosal Immunization with HBc-E18-3 VLPs Induces Long-Lasting Intestinal IgG and Provides a Candidate Strategy for Intervention of FcRn-Related Autoimmune Injury https://www.biorxiv.org/content/10.64898/2026.08.10.743934v1
Floss-Mediated Gingival Mucosal Immunization with HBc-E18-3 VLPs Induces Long-Lasting Intestinal IgG and Provides a Candidate Strategy for Intervention of FcRn-Related Autoimmune Injury https://www.biorxiv.org/content/10.64898/2026.08.10.743934v1
August 15, 2026 at 4:15 AM
Floss-Mediated Gingival Mucosal Immunization with HBc-E18-3 VLPs Induces Long-Lasting Intestinal IgG and Provides a Candidate Strategy for Intervention of FcRn-Related Autoimmune Injury https://www.biorxiv.org/content/10.64898/2026.08.10.743934v1
Placental FcRn selectively transports IgG to the fetus while largely excluding albumin. That difference could help guide biologic medicines built for long plasma half-lives with reduced fetal exposure. doi.org/hcfmzv
Placental transport mechanism could guide safer biologic medicines during pregnancy
Biologic medicines have transformed the treatment of cancer, autoimmune diseases, migraine, inflammatory disorders and many other conditions.
medicalxpress.com
August 14, 2026 at 6:00 PM
Placental FcRn selectively transports IgG to the fetus while largely excluding albumin. That difference could help guide biologic medicines built for long plasma half-lives with reduced fetal exposure. doi.org/hcfmzv